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Background: Patients with COPD are at risk of non-tuberculous mycobacterial infection (NTM). This study examined
the histology of lung tissue from COPD patients following lung volume reduction with particular focus on evidence
of mycobacterial infection.
Methods: Retrospective histological study of 142 consecutive lung volume reduction surgical specimens (126
separate patients) at Royal Brompton Hospital between 2000 – 2013, with prospectively collected preoperative data
on exacerbation rate, lung function and body mass index.
Results: 92% of patients had at least one other histological diagnosis in addition to emphysema. 10% of specimens
had histological evidence of mycobacterial infection, one with co-existent aspergilloma. Mycobacteria were only
identified in those patients with granulomas that were necrotising. These patients had higher exacerbation rates,
lower TLCO and FEV1.
Conclusion: A proportion of severe COPD patients will have evidence of mycobacterial infection despite lack of
clinical and radiological suspicion. This may have implications for long-term management of these patients.
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Non-tuberculosis mycobacteria (NTM) are a group of
widely distributed environmental mycobacteria (other
than tuberculosis and leprosy). There are over 100 species
with varying degrees of pathogenicity [1]. Pulmonary
disease is the most common manifestation and is com-
monly diagnosed using American Thoracic Society
(ATS) guidelines. A diagnosis requires pulmonary
symptoms, and nodular or cavitatory opacities on im-
aging, in addition to positive cultures from two or
more separate sputum samples or one positive culture
from tissue/bronchial lavage samples [2,3]. The preva-
lence of NTM infection is increasing worldwide which* Correspondence: m.loebinger@rbht.nhs.uk
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unless otherwise stated.may be due in part to increased exposure and numbers
of susceptible patients [4].
NTM are opportunistic bacteria and are therefore
more likely to cause disease when there are defects in
local or systemic host immunity. Patients with pre-
existing lung conditions, such as COPD, cystic fibrosis
(CF) and bronchiectasis, are shown to have a higher as-
sociation with NTM infection [2,5,6].
Lung volume reduction surgery (LVRS) and bullectomy
are surgical procedures directed at COPD patients in whom
optimal medical treatment has failed to reduce their symp-
toms. These procedures improve lung mechanics in hetero-
geneous emphysema by removing the areas of lung with
the greatest destruction [7-10]. These procedures provide a
resected tissue specimen, which is routinely sent for
histopathological analysis. We have previously reported
the safety outcomes in this population [11]. This studyd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Demographic and surgical data
Demographic and surgical data
No. of patients 126
Total no. of operations 142
Age, yr (mean ± SD) (Range: 29 – 81 yr) 57.3 ± 9.74
Gender M 107 (75%)
F 35 (25%)
BMI (mean ± SD) 23.52 ± 4.16
Exacerbations/year (mean ± SD) 2.59 ± 2.61
FEV1, % predicted (mean ± SD) 36.30 ± 16.83
FVC, % predicted (mean ± SD) 81.27 ± 20.52
TLCO, % predicted (mean ± SD) 40.47 ± 16.99
RV, % predicted (mean ± SD) 216.48 ± 59.29
TLC, % predicted (mean ± SD) 128.61 ± 20.43
LVRS Operations 112 (79%)
Bilateral 27 (24%)
Unilateral* 85 (76%)
Right 52 (61%)
Left 33 (39%)
Bullectomy^ 30 (21%)
*15 patients had both R and L LVRS done on separate dates.
^1 patient had both R and L bullectomy on separate dates.
BMI: body mass index; FEV1: forced expiratory volume in 1 s; LVRS: lung
volume reduction surgery. Data shown as mean ± Standard Deviation (SD).
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LVRS and bullectomy for histological diagnoses in
addition to emphysema, with a particular reference to
evidence of mycobacterial infection.
Methods
The clinical records of 126 consecutive patients who
underwent LVRS or bullectomy at the Royal Brompton
Hospital from 2000–2013, were retrospectively reviewed
for demographic, clinical, lung function, surgical, radio-
logical, microbiological and histological data. All patients
underwent pulmonary rehabilitation prior to surgery and
had a thorough pre-operative work up, including chest
radiographs (CXR) and/or CT scans and lung function
tests. Indications for LVRS/bullectomy: emphysema with
destruction and marked hyperinflation; substantial bulla
identified on CXR; a marked functional impairment; a
marked reduction in activities of daily living; a failure of
maximum medical treatment to reduce symptoms; het-
erogeneous disease with obvious apical target areas [7].
The LVRS or bullectomy was performed unilaterally
using lateral thoracotomy or bilaterally via median sternot-
omy. Video assisted thoroscopic surgery (VATS) procedure
was used for either bilateral or unilateral procedures.
Pathological diagnoses in addition to emphysema
mentioned in histology reports were noted, with special
focus on evidence of mycobacterial infection (necrotising
granulomas with or without positive Ziehl-Neilson (ZN)
staining for acid-fast bacilli (AFB)). All lung nodules
identified pre-operatively by imaging or identified in
resected specimens were recorded. Exacerbation rates
were defined as the number of COPD exacerbations for
the year prior to surgery as recorded in the clinical records.
Statistics are reported as mean ± standard deviation (SD).
The groups (evidence of mycobacterium or not) were
compared in the following variables: sex, age, BMI, ex-
acerbation rate, lung function pre-operation (% predicted),
pre-operation FVC (% predicted), pre-operation TICO
(% predicted), pre-operation TLC (% predicted) and pre-
operation RV (% predicted). Groups were compared in the
distribution of sex using Fisher’s Exact test since the Chi-
Squared test was invalid. If the distributional assumption of
normality could be made, groups were compared using the
independent samples t-test (test statistic denoted by t). If
equal variances could not be assumed between groups,
Satterthwaite’s approximation to the degrees of freedom
was made. The Mann–Whitney test was used to compare
the mycobacterium groups in exacerbation rate since the
assumption of normality could not be made. A multivariate
analysis was performed using binary logistic regression,
with mycobacterium status (present versus absent) as the
outcome variable. All explanatory variables described above
were entered into the model. The explanatory varia-
bles were categorised as follows: sex (male, female), age(<60, ≥60 years), BMI (<18.5 kgm−2, ≥18.5 kgm−2), exacer-
bation rate (<2 per year, ≥2 per year), FEV1 (% predicted)
(<40%, ≥40%), FVC (% predicted) (<80%, ≥80%), TICO
(% predicted) (<40%, ≥40%), TLC (% predicted) (<125%,
≥125%) and RV (% predicted) (<200%, ≥200%). The odds
ratios were adjusted for all other explanatory variables in
the model. The critical level of significance was set at 0.05
(i.e. 5%). 95% Confidence Intervals are denoted by 95% CI.
The Research Office of the Royal Brompton has ruled that
this is a service evaluation and that formal ethical approval
was not required.
Results
The demographic and surgical data of the 126 patients are
shown in Table 1. In total, 142 specimens were obtained
from 142 procedures, including 16 patients who had two
operations on separate occasions. The mean age was
57 years and 75% of the patients were male. The majority
(95%) were Caucasian, with 5 Asian and 1 African patient.
Pulmonary function tests showed a severe obstructive
lung disease with a mean FEV1 of 36.3% of normal, and
severe air trapping with a residual volume of >200% of
normal. There was an average of 2.59 exacerbations per
year. Early mortality (≤30 postoperative days) was 1 of 126
patients. In view of the severity of the emphysema over
96% patients were on inhaled steroids. There was some
Figure 1 Flowchart illustrating histopathological results. 3 of 14 specimens were cultured positive for NTM infection. HRCT: High resolution
computed tomography; NTM: Non-tuberculous mycobacterium.
Figure 2 Chest CT scan showing emphysema and nodule (arrow).
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corded in clinical notes; 3 patients had no pre-operative
FEV1 and FVC recorded; 5 patients had no pre-operative
TLCO; 6 patients had no pre-operative TLC and 7 pa-
tients had no pre-operative RV recorded.
Fourteen histological reports had evidence of mycobac-
terial infection, with one or more necrotising granulomas,
and 8 of which showed acid-fast bacilli on Ziehl-Nielsen
staining. As there was no clinical suspicion of mycobacte-
rial infection at the time of the operation, a minority (4/14
samples) were sent for mycobacterial tissue culture; and 2
specimens subsequently grew Mycobacterium xenopi. Al-
though there were no other tissue cultures, a further 8 pa-
tients had sputum samples cultured for mycobacteria with
1 of these samples culturing mycobacterium kansasii
(Figure 1). In one case in which AFBs were present, an
aspergilloma was also noted. Fungal stains on the remaining
cases were negative. HRCT scans (median time from ope-
ration date 28 days (1–47)) were reviewed retrospectively in
the patients with histopathological evidence of necrotising
granulomas (13/14 scans available) to specifically look for
nodules and CT features compatible with mycobacterial
disease. Twelve out of these 13 scans had evidence of small
nodules (3-15 mm) (Figure 2). Even with the knowledge of
Table 2 Histological findings other than Emphysema (%
of 142 operations, most specimens had more than one)
Histological findings other than Emphysema (% of 142 operations)
Chronic inflammation 54 (38%)
Pleural/Interstitial fibrosis 49 (36%)
Respiratory/Chronic bronchiolitis 28 (20%)
Organising pneumonia 22 (16%)
Reactive mesothelial hyperplasia 17 (12%)
Non– necrotising granuloma 16 (11%)
Nectrotising granuloma 14 (10%)
Hyperplastic type II pneumocytes 7 (6%)
Aspergillus infection 5 (4%)
Malignancies: 3 (2%)
Sarcomatoid carcinoma (not seen on CT) 1
Adenocarcinoma, mod. Differentiated (both seen on CT) 2
Tumourlet 1 (0.8%)
Focal neuroendocrine hyperplasia 1 (0.8%)
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that were suggestive of a radiological diagnosis of non-
tuberculous mycobacterial infection.
In addition to evidence of mycobacterial infection, ad-
ditional histological diagnoses were made in a number ofTable 3 Comparison of selected variables between patients w
Age, BMI, Exacerbations/Year and Pre-Operative Lung Function of patient
mycobacterium evidence (Mean ± SD)
No Mycobacterium Myco
No. of patients 112 14
Male: Female ratio 89:23 9:5
Age, years 57.5 ± 10.39 63.0 ±
BMI 23.9 ± 4.04 22.1 ±
Exacerbations/Year 2.2 ± 2.40 5.3 ± 2
FEV1, % predicted 37.7 ± 17.17 25.0 ±
FVC, % predicted 81.7 ± 21.44 74.1 ±
TLCO, % predicted 42.6 ± 17.88 30.7 ±
RV, % predicted 218.1 ± 59.20 215.6 ±
TLC, % predicted 127.8 ± 21.49 130.0 ±
Data shown as mean ± SD. FEV1: Forced expiratory volume in 1 sec; FVC: Forced vita
volume; TLC: Total lung capacity. These variables are all shown as percentage predicases as shown in Table 2. There were a further 15 pa-
tients with evidence of non-necrotising granulomas. No
organisms were seen in the five cases where Ziehl-Nielsen
and Grocott staining was undertaken on the granuloma-
tous areas.
A comparison of variables (listed in methods) was made
between specimens with evidence of mycobacterial infec-
tion (14 of 142) and specimens without (128 of 142). This
comparison is shown in Table 3. Patients with histological
evidence of mycobacterium infection had a significantly
lower pre-operative FEV1 (p < 0.001; 95% CI: −17.55
to −7.84) and a significantly higher number of exacer-
bations/year (p < 0.001) compared to patients without
evidence of mycobacterium infection. In addition, patients
with histological evidence of mycobacterium infection had
a significantly lower TLCO (p < 0.001; CI: −18.05 to −5.85).
The independent effect of the variables upon mycobac-
terium (absent or present) was further investigated using
binary logistic regression. Exacerbation rate remained as
independently associated with the presence of mycobac-
terial disease with this model (Table 4).
Discussion
This is the first study, to our knowledge, using resected
lung specimens from LVRS/bullectomy procedures to esti-
mate the prevalence of concurrent clinically unexpectedith and without evidence of mycobacterium infection
s without mycobacterium evidence compared to those with
bacterium P value 95% CI
0.303
6.02 0.054
(95% CI: −0.096-11.15)
4.36 0.110
(95% CI: −4.15-0.42)
.69 <0.001
(Mann–Whitney Test, 95% CI not possible)
6.58 <0.001
(95% CI: −17.55 -7.84)
15.00 0.207
(95% CI: −19.23-4.20)
9.11 <0.001
(95% CI: −18.05-- 5.85)
63.17 0.881
(95% CI: −36.11-31.02)
23.10 0.722
(95% CI: −9.99- 14.39)
l capacity; TLCO: Transfer factor of the lung for carbon monoxide; RV: Residual
cted.
Table 4 Multivariate comparison of selected variables
between patients with and without evidence of
mycobacterium infection
Odds ratio (95%
confidence interval)
P-Value
Sex
Male 0.79 (0.12, 4.98) 0.798
Female
Age
<60 0.76 (0.15, 3.78) 0.740
≥60 years
BMI
<18.5 kgm−2 0.13 (0.01, 1.50) 0.102
≥18.5 kgm−2
Exacerbation rate
<2 per year 50.24 (4.19, 602.01) 0.002
≥2 per year
Pre-operation FEV1 (% predicted)
<40% 1.08 (0.8, 15.45) 0.954
≥40%
Pre-operation FVC (% predicted)
<80% 0.24 (0.04, 1.37) 0.108
≥80%
Pre-operation TICO (% predicted)
<40% 0.17 (0.03, 1.09) 0.061
≥40%
Pre-operation TLC (% predicted)
<125% 5.86 (0.53, 64.6) 0.149
≥125%
Pre-operation RV (% predicted)
<200% 0.29 (0.03, 2.52) 0.261
≥200%
Results of binary logistic regression. The odds ratio is the odds of
mycobacterium (present) if risk factor category present relative to other risk
factors. All odds ratios are adjusted for all other risk factors in the model.
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11% of 126 patients (10% of 142 specimens) had histo-
logical evidence of mycobacterial infection (necrotising
granuloma, with or without AFB). A small number of pre-
vious studies [8,12,13] have likewise found evidence of a
wide range of histopathological diagnoses in addition to
emphysema in surgical specimens, including neoplastic
nodules and interstitial fibrosis, however none of these
studies have previously reported any evidence of mycobac-
terial disease on histology.
COPD and other chronic respiratory conditions have
been shown to confer a high risk of NTM infection. One
study [14], showed that patients, already diagnosed withNTM (according to the ATS criteria [2]), were likely to
also have COPD (odds ratio: 15.7). This study also
showed there was longstanding COPD (i.e. they had
COPD for more than 5 years before NTM diagnosis) in
42.8% of all NTM patients [14]. Furthermore, inhaled
steroid usage and dosage conferred an additional risk for
NTM after adjustment for oral steroid use and co-
morbidities [14]. A similar US study [15] looked at diag-
nosed cases of NTM and found a high prevalence of
co-morbid COPD in patients with NTM infection (28%).
This present study differs by taking the opposite ap-
proach and providing an assessment of the prevalence of
mycobacterial disease in a consecutive series of patients
undergoing surgery for COPD, and importantly with
no prior clinical indicators or suspicion of mycobac-
terial disease.
It is difficult to determine the clinical significance of
these findings. These patients would not fulfil the criteria
for NTM pulmonary disease and there was no morbidity
that could be specifically attributed to these findings. In
addition, outcome is difficult to determine following surgi-
cal removal of the areas that are likely to represent myco-
bacterial disease. In this study, the pre-operative FEV1 and
TLCO were significantly lower, and the exacerbation rate
(no. of COPD exacerbations in the year prior to surgery)
was significantly higher for patients with evidence of
mycobacterial infection compared to those patients with-
out evidence of mycobacterial infection. However, it is not
clear from our results whether these may be caused by the
concurrent NTM infection in patients with COPD, or
whether patients with more severe COPD (signalled by
worse lung function and exacerbation rates) are more sus-
ceptible to NTM infection. The association was strongest
on multivariate analysis between exacerbation rate and
histological evidence of mycobacterial disease, however, it
would not be sensible to exclude the importance of the
variables found to be significant on the univariate analysis,
because of the sample size.
There are other important messages that come out of
these findings. Subclinical mycobacterial disease can be
present in patients with severe COPD and this may have
implications for COPD management. Long term, pro-
phylactic macrolide therapy has recently been suggested
as a therapeutic strategy for COPD patients with regular
infections [16]. Before commencing this however, it is
important to screen for NTM disease as macrolide mo-
notherapy is contraindicated in such instances, due to
the risk of macrolide resistance and worse prognosis [2].
These results indicate a further level of complexity to
therapeutic decision-making, if there is a need to also
exclude subclinical NTM infection as discovered in a
significant proportion of surgical specimens.
Due to the nature of this study, there are several limi-
tations. The diagnosis of mycobacterial disease in this
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findings. There was no clinical suspicion of mycobacte-
rial disease in these patients undergoing LVRS. As such,
samples were routinely sent for histology but not for cul-
ture. This apparent limitation actually serves to highlight
the importance and relevance of this work. There have
been no previous similar studies suggesting such a high
potential rate of mycobacterial disease. It demonstrates
that samples should be sent for culture but also that
mycobacterial disease needs to be actively considered in
this population. The lack of definitive culture is a com-
mon occurrence in mycobacterial disease as highlighted
by the lack of a positive TB culture in over 40% of treated
TB cases in the UK [17]. The diagnosis of mycobacterial
disease was nevertheless reasonably confident, with necro-
tising granulomas in all 14 patients and positive AFB
staining in 8/14 specimens. Also, histological examination
of the tissue has an advantage over microbiological diag-
nosis of being able to assess the activity and chronicity of
the infection, through an assessment of the relative abun-
dance of inflammation, fibrosis and necrosis. Certain fungi
can cause necrotising granulomas such as histoplasmosis,
although we would have expected to see these with a
Grocott stain. It is likely that this study will tend to un-
derestimate the number of patients with mycobacterial
infection. Firstly, a proportion of the non-necrotising
granulomas that were also found in a further 16 patients
may represent burnt-out or inactive mycobacterial disease.
However, on reviewing those without necrosis, no evi-
dence of organisms was seen and our data suggest that
this histological feature may therefore be an important
one in assessing the risk of active disease. In addition, the
non-necrotising (n = 15) group had clinical features more
in common with the ‘non mycobacterial’ group and on a
separate analysis had significantly different exacerbation
rates, FEV1 and TLCO to the necrotising (n = 14) group)
(data not shown). Secondly, this study would not capture
patients with evidence of mycobacterial disease outside of
the anatomical area biopsied. Although accurate differen-
tiation between NTM and Mycobacterium tuberculosis is
not possible without culture, TB was not suspected in any
of the cases clinically and Interferon Gamma Release
Assays (IGRA), although not perfect, were only positive in
1/5 patients where this was performed (this patient went
on to culture M. kansasii which is known to produce a
positive IGRA). It is also important to note that these re-
sults relate to COPD patients who had disease that was
suitable for LVRS and may not necessarily be able to be
generalised across all severe COPD patients.
In addition to evidence of mycobacterial infection, a
wide range of other histological diagnoses were made in
addition to emphysema. This has been seen in other
similar studies [8,12] and is an indication of the patho-
logy that co-exists with severe emphysema.Conclusion
A high proportion of patients with end-stage COPD re-
quiring surgical treatment had histopathological evidence
of clinically and radiologically unsuspected mycobacterial
infection. Despite the study limitations of lack of culture
data and the unknown clinical significance, this does
provide an important clinical message. Mycobacteria are
more common in COPD patients than suspected, par-
ticularly in patients with more severe disease or multiple
exacerbations, and this should be considered and appro-
priate cultures obtained.
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